Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Aims</h3><p>Left ventricular (LV) thrombus is increasingly detected in patients with and without ischaemic heart disease due to the increased availability of cardiac magnetic resonance imaging. Risk factors include anterior ST elevation myocardial infarction, delayed reperfusion therapy, and non‐ischaemic cardiomyopathy with severe LV systolic dysfunction. We aimed to report the characteristics and outcomes of patients with LV thrombus treated with either vitamin K antagonist (VKA) or direct oral anticoagulants (DOAC) with a view to describing differences in efficacy, specifically, subsequent thromboembolic events, thrombus resolution, and also side effects of therapy including clinically significant bleeding.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods and results</h3><p>We conducted a retrospective, observational cohort study of patients diagnosed with LV thrombus between 1 December 2012 and 30 June 2018 and treated with either DOAC or VKA. We recorded patient demographics, past medical history, prescribed medications, and baseline investigations. The primary outcomes were rates of thromboembolism and clinically significant bleeding, with secondary outcomes of thrombus resolution on repeat cardiac imaging, repeat hospitalization, and all‐cause mortality. During the study period, 84 patients were diagnosed with and managed for LV thrombus. Of these, 62 received VKA and 22 DOAC including 13 prescribed rivaroxaban, eight apixaban, and one dabigatran. Most patients 75 (89%) were male with an average age of 62 ± 14 years. Ischaemic heart disease was the cause of LV impairment in 73 (87%) patients. Baseline characteristics were similar between groups at baseline. Most <i>n</i> = 55 (65%) were co‐prescribed a single antiplatelet agent and 32 (38%) received dual‐antiplatelet therapy. During an average follow‐up of 3.0 ± 1.4 years, there were no statistically significant differences between VKA and DOAC in rates of stroke (2% vs. 0%, <i>P</i> = 0.55), other thromboemboli (2% vs. 0%, <i>P</i> = 0.55), or clinically significant bleeding (10% vs. 0%, <i>P</i> = 0.13). The average interval to cardiac imaging follow‐up was 233 ± 251 days and was not different between groups (<i>P</i> = 0.83), and there was no difference in the rate of resolution of thrombus (76% vs. 65% <i>P</i> = 0.33). Rehospitalization (50% vs. 45%: <i>P</i> = 0.53) and all‐cause mortality (10% vs. 14%; <i>P</i> = 0.61) were also similar. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Our data suggest that DOACs are likely to be at least as effective and safe as VKA for stroke prevention in patients with LV thrombus and, despite their lack of a licence for this indication, are therefore likely to represent a reasonable and more convenient option for this setting. The optimal timing and type of anticoagulation for LV thrombus, as well as the role of screening for high‐risk patients, should be tested in prospective, randomized trials.</p></section>

Novel oral anticoagulant in treatment of left ventricular thrombus in acute coronary syndrome – A case series

A meta-summary of case reports of non-vitamin K antagonist oral anticoagulant use in patients with left ventricular thrombus

Rivaroxaban versus Vitamin K Antagonists (warfarin) based on the triple therapy for left ventricular thrombus after ST-Elevation myocardial infarction

Direct oral anticoagulants compared to vitamin K antagonist for the management of left ventricular thrombus

Individualized anti-thrombotic therapy for acute myocardial infarction complicated with left ventricular thrombus: A case report

Comparative analysis of vitamin K antagonists and direct oral anticoagulants for left ventricular thrombus management: a retrospective study utilising TriNetX

Warfarin Vs. Direct Oral Anticoagulants For Left Ventricle Thrombus Treatment

Prophylactic Anticoagulation to Prevent Left Ventricular Thrombus Following Acute Myocardial Infarction: A Systematic Review and Meta-Analysis

Anticoagulation combined with antiplatelet therapy in patients with left ventricular thrombus after first acute myocardial infarction

Dabigatran Added to Dual Antiplatelet Therapy to Treat a Left Ventricular Thrombus in an 87 Year Old Patient With Myocardial Infarction and Very High Bleeding Risk

Anticoagulation for Left Ventricular Thrombosis Post-Myocardial Infarction – Current Recommendations and Future Perspectives

Daily 10 mg rivaroxaban as a therapy for ventricular thrombus related to left ventricular non-compaction cardiomyopathy: A case report.

Oral anticoagulation in patients with left ventricular thrombus: a systematic review and network meta-analysis with reconstructed time-to-event data

Rationale and Design of a Prospective Multi-Center Randomized Trial of EARLY Treatment by Rivaroxaban Versus Warfarin in ST-segment Elevation MYOcardial Infarction with Left Ventricular Thrombus (EARLY-MYO-LVT Trial).

Non–vitamin K oral anticoagulants versus warfarin for the treatment of left ventricular thrombus

Efficacy and Safety Profile of Novel Oral Anticoagulants in the Treatment of Left Atrial Thrombosis: A Systematic Review and Meta-Analysis

Direct oral anticoagulant use in left ventricular thrombus

Reversal of Bioprosthetic Aortic Valve Thrombosis Using Rivaroxaban—A Case Report

Analysis of safety and outcome of use of NOAC in intracardiac thrombi over warfarin

Left ventricular thrombus after acute myocardial infarction: screening, prevention, and treatment

Abstract WP19: Is Direct Oral Anticoagulant More Effective Than Warfarin to Reduce Size of Left Atrial Thrombus in Stroke Patients?